Hiroshi Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroshi Suzuki has a total of 305 co-authors. Here are the top co-authors by number of shared publications:
- Yoshitaka Iso
Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan
12 shared publications Takashi Katagiri
Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
8 shared publicationsAtsuo Maeda
Department of Internal Medicine, Division of Cardiology, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501, Japan
7 shared publications- Hiroyoshi Mori
Division of Cardiology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Kanagawa, Japan
7 shared publications Yoshitaka Iso
Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan
7 shared publicationsKazuma Tashiro
6 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (11)
Pheochromocytoma masquerading as fulminant myocarditis with marked interleukin-6 elevation: a case report
Background: Pheochromocytoma is a rare cause of cardiogenic shock with diverse cardiovascular manifestations. Although catecholamine-induced cardiomyopathy is well recognized, presentations closely resembling fulminant myocarditis are uncommon and diagnostically challenging. The role of cytokine-mediated inflammatory activation in such presentations is not well defined. Case summary: A previously healthy woman in her 30s presented with fever, ventricular arrhythmias, and severe left ventricular dysfunction, rapidly progressing to cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation and Impella support. Fulminant myocarditis was initially suspected based on clinical, electrocardiographic, and biomarker findings, and immunomodulatory therapy was initiated. Although transient improvement was observed, endomyocardial biopsy showed minimal inflammatory infiltration. Subsequent computed tomography revealed a left adrenal mass, and biochemical testing confirmed markedly elevated catecholamines. Notably, interleukin-6 (IL-6) was also markedly elevated relative to C-reactive protein. Despite initiation of α-blockade, the patient developed recurrent haemodynamic collapse, necessitating emergency adrenalectomy. Pathological examination confirmed a necrotic pheochromocytoma, but the patient died of refractory multiorgan failure. Discussion: This case illustrates how pheochromocytoma can closely mimic fulminant myocarditis, with a risk of diagnostic anchoring. The coexistence of marked IL-6 elevation and catecholamine excess raises the possibility of concomitant inflammatory activation, although a causal role of IL-6 cannot be established. Recognition of this pattern is important to prompt reconsideration of endocrine aetiologies in myocarditis-like cardiogenic shock.
- 26 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (11)
Open AccessPheochromocytoma masquerading as fulminant myocarditis with marked interleukin-6 elevation: a case report
Background: Pheochromocytoma is a rare cause of cardiogenic shock with diverse cardiovascular manifestations. Although catecholamine-induced cardiomyopathy is well recognized, presentations closely resembling fulminant myocarditis are uncommon and diagnostically challenging. The role of cytokine-mediated inflammatory activation in such presentations is not well defined. Case summary: A previously healthy woman in her 30s presented with fever, ventricular arrhythmias, and severe left ventricular dysfunction, rapidly progressing to cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation and Impella support. Fulminant myocarditis was initially suspected based on clinical, electrocardiographic, and biomarker findings, and immunomodulatory therapy was initiated. Although transient improvement was observed, endomyocardial biopsy showed minimal inflammatory infiltration. Subsequent computed tomography revealed a left adrenal mass, and biochemical testing confirmed markedly elevated catecholamines. Notably, interleukin-6 (IL-6) was also markedly elevated relative to C-reactive protein. Despite initiation of α-blockade, the patient developed recurrent haemodynamic collapse, necessitating emergency adrenalectomy. Pathological examination confirmed a necrotic pheochromocytoma, but the patient died of refractory multiorgan failure. Discussion: This case illustrates how pheochromocytoma can closely mimic fulminant myocarditis, with a risk of diagnostic anchoring. The coexistence of marked IL-6 elevation and catecholamine excess raises the possibility of concomitant inflammatory activation, although a causal role of IL-6 cannot be established. Recognition of this pattern is important to prompt reconsideration of endocrine aetiologies in myocarditis-like cardiogenic shock.
- Open Access
- 5 March 2026
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 26 (3) , 301-304
Focal atrial fibrillation mimicking atrial tachycardia: Which mapping approach identifies the true source?
- 5 March 2026
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 26 (3) , 301-304
Open AccessFocal atrial fibrillation mimicking atrial tachycardia: Which mapping approach identifies the true source?
- Open Access
- 19 November 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (6)
Association Between History of Rhythm Control Therapy and Clinical Outcomes in Atrial Fibrillation Patients With Stable Coronary Artery Disease: A Sub‐Analysis of the AFIRE Trial
Background: Rhythm control therapy improves the quality of life and prognosis of patients with atrial fibrillation (AF). We assessed the characteristics and clinical outcomes of AF patients with stable coronary artery disease (CAD) undergoing rhythm control therapy. Methods: We analyzed 2215 participants from the Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial, including 588 patients who received rhythm control therapy and 1627 who did not. Results: At baseline, patients who received rhythm control therapy were generally younger, exhibited a higher prevalence of paroxysmal AF, experienced less heart failure, and had lower CHADS2 scores (CHF, hypertension, age ≥ 75 years, type 2 diabetes, and previous stroke or transient ischemic attack [doubled]) than those who did not. Among the rivaroxaban monotherapy and combination therapy groups, patients with a history of rhythm control therapy showed a lower incidence of the primary efficacy endpoint (a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death). However, following multivariate analysis and propensity score matching, no statistically significant difference in the primary efficacy endpoint was observed between patients with and without prior rhythm control therapy (adjusted HR 0.75, 95% CI 0.37–1.51, p = 0.43 in the rivaroxaban group; adjusted HR 0.75, 95% CI 0.43–1.30, p = 0.30 in the combination therapy group). Conclusions: The initially observed benefit of rhythm control therapy was not significant after adjusting for baseline characteristics in patients with AF and stable CAD treated with rivaroxaban with or without additional antiplatelet therapy.
- 19 November 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (6)
Open AccessAssociation Between History of Rhythm Control Therapy and Clinical Outcomes in Atrial Fibrillation Patients With Stable Coronary Artery Disease: A Sub‐Analysis of the AFIRE Trial
Background: Rhythm control therapy improves the quality of life and prognosis of patients with atrial fibrillation (AF). We assessed the characteristics and clinical outcomes of AF patients with stable coronary artery disease (CAD) undergoing rhythm control therapy. Methods: We analyzed 2215 participants from the Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial, including 588 patients who received rhythm control therapy and 1627 who did not. Results: At baseline, patients who received rhythm control therapy were generally younger, exhibited a higher prevalence of paroxysmal AF, experienced less heart failure, and had lower CHADS2 scores (CHF, hypertension, age ≥ 75 years, type 2 diabetes, and previous stroke or transient ischemic attack [doubled]) than those who did not. Among the rivaroxaban monotherapy and combination therapy groups, patients with a history of rhythm control therapy showed a lower incidence of the primary efficacy endpoint (a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death). However, following multivariate analysis and propensity score matching, no statistically significant difference in the primary efficacy endpoint was observed between patients with and without prior rhythm control therapy (adjusted HR 0.75, 95% CI 0.37–1.51, p = 0.43 in the rivaroxaban group; adjusted HR 0.75, 95% CI 0.43–1.30, p = 0.30 in the combination therapy group). Conclusions: The initially observed benefit of rhythm control therapy was not significant after adjusting for baseline characteristics in patients with AF and stable CAD treated with rivaroxaban with or without additional antiplatelet therapy.
- Open Access
- 22 February 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (3) , 339-340
Treatment for Acute Limb Ischemia ― Japanese Real-World Data From Active Facilities ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 22 February 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (3) , 339-340
Open AccessTreatment for Acute Limb Ischemia ― Japanese Real-World Data From Active Facilities ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 1 May 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-3
Pre-treatment study for barrier-less Ruthenium filling into single damascene via of sub 20nm hole size
Ru filling in small vias is challenging. Voids in the via will cause high via resistance. Ru filling with dep-etch sequence helps to minimize void formation; however, it is not productivity friendly. We report Ru fill without void in sub 20nm diameter vias using a surface treatment. New surface treatment has been introduced as a treatment to manage the Ru deposition rate on SiO2 and the bottom metal.
- 1 May 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-3
Pre-treatment study for barrier-less Ruthenium filling into single damascene via of sub 20nm hole size
Ru filling in small vias is challenging. Voids in the via will cause high via resistance. Ru filling with dep-etch sequence helps to minimize void formation; however, it is not productivity friendly. We report Ru fill without void in sub 20nm diameter vias using a surface treatment. New surface treatment has been introduced as a treatment to manage the Ru deposition rate on SiO2 and the bottom metal.
- Open Access
- 24 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1049
Mesenchymal Stem/Stromal Cells in Skeletal Muscle Are Pro-Angiogenic, and the Effect Is Potentiated by Erythropoietin
The aim of this study was to investigate the angiogenic potential of skeletal muscle mesenchymal stem/stromal cells (mMSCs). Platelet-derived growth factor receptor (PDGFR)-α positive mMSCs secreted vascular endothelial growth factor (VEGF) and hepatocyte growth factor when cultured in an ELISA assay. The mMSC-medium significantly induced endothelial tube formation in an in vitro angiogenesis assay. The mMSC implantation promoted capillary growth in rat limb ischemia models. Upon identifying the erythropoietin receptor (Epo-R) in the mMSCs, we examined how Epo affected the cells. Epo stimulation enhanced the phosphorylation of Akt and STAT3 in the mMSCs and significantly promoted cellular proliferation. Next, Epo was directly administered into the rats’ ischemic hindlimb muscles. PDGFR-α positive mMSCs in the interstitial area of muscles expressed VEGF and proliferating cell markers. The proliferating cell index was significantly higher in the ischemic limbs of Epo-treated rats than in untreated controls. Investigations by laser Doppler perfusion imaging and immunohistochemistry demonstrated significantly improved perfusion recovery and capillary growth in the Epo-treated groups versus the control groups. Taken together, the results of this study demonstrated that mMSCs possessed a pro-angiogenic property, were activated by Epo, and potentially contributed to capillary growth in skeletal muscle after ischemic injury.
- 24 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1049
Open AccessMesenchymal Stem/Stromal Cells in Skeletal Muscle Are Pro-Angiogenic, and the Effect Is Potentiated by Erythropoietin
The aim of this study was to investigate the angiogenic potential of skeletal muscle mesenchymal stem/stromal cells (mMSCs). Platelet-derived growth factor receptor (PDGFR)-α positive mMSCs secreted vascular endothelial growth factor (VEGF) and hepatocyte growth factor when cultured in an ELISA assay. The mMSC-medium significantly induced endothelial tube formation in an in vitro angiogenesis assay. The mMSC implantation promoted capillary growth in rat limb ischemia models. Upon identifying the erythropoietin receptor (Epo-R) in the mMSCs, we examined how Epo affected the cells. Epo stimulation enhanced the phosphorylation of Akt and STAT3 in the mMSCs and significantly promoted cellular proliferation. Next, Epo was directly administered into the rats’ ischemic hindlimb muscles. PDGFR-α positive mMSCs in the interstitial area of muscles expressed VEGF and proliferating cell markers. The proliferating cell index was significantly higher in the ischemic limbs of Epo-treated rats than in untreated controls. Investigations by laser Doppler perfusion imaging and immunohistochemistry demonstrated significantly improved perfusion recovery and capillary growth in the Epo-treated groups versus the control groups. Taken together, the results of this study demonstrated that mMSCs possessed a pro-angiogenic property, were activated by Epo, and potentially contributed to capillary growth in skeletal muscle after ischemic injury.
- Open Access
- 1 January 2023
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 10 (1) , 12
Cardiac Structure and Cardiorespiratory Fitness in Young Male Japanese Rugby Athletes
Limited data are available on athlete’s heart for rugby athletes. This study aimed to investigate cardiac structure and its relationship with cardiorespiratory fitness in young Japanese rugby athletes. A prospective cross-sectional study using echocardiography and cardiopulmonary exercise testing (CPET) was conducted on 114 male collegiate rugby players. There was a higher prevalence of increased left ventricular (LV), atrial, and aortic dimensions in the young athletes than that in previously published reports, whereas the wall thickness was within the normal range. Anthropometry and CPET analyses indicated that the forwards and backs presented muscular and endurance phenotypes, respectively. Indexed LV and aortic dimensions were significantly larger in the backs than in the forwards, and the dimensions significantly correlated with oxygen uptake measured by CPET. On the four-tiered classification for LV hypertrophy, abnormal LV geometry was found in 16% of the athletes. Notably, the resting systolic blood pressure was significantly higher in athletes with concentric abnormal geometry than in the other geometry groups, regardless of their field positions. Japanese young athletes may exhibit unique phenotypes of cardiac remodeling in association with their fitness characteristics. The four-tiered LV geometry classification potentially offers information regarding the subclinical cardiovascular risks of young athletes.
- 1 January 2023
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 10 (1) , 12
Open AccessCardiac Structure and Cardiorespiratory Fitness in Young Male Japanese Rugby Athletes
Limited data are available on athlete’s heart for rugby athletes. This study aimed to investigate cardiac structure and its relationship with cardiorespiratory fitness in young Japanese rugby athletes. A prospective cross-sectional study using echocardiography and cardiopulmonary exercise testing (CPET) was conducted on 114 male collegiate rugby players. There was a higher prevalence of increased left ventricular (LV), atrial, and aortic dimensions in the young athletes than that in previously published reports, whereas the wall thickness was within the normal range. Anthropometry and CPET analyses indicated that the forwards and backs presented muscular and endurance phenotypes, respectively. Indexed LV and aortic dimensions were significantly larger in the backs than in the forwards, and the dimensions significantly correlated with oxygen uptake measured by CPET. On the four-tiered classification for LV hypertrophy, abnormal LV geometry was found in 16% of the athletes. Notably, the resting systolic blood pressure was significantly higher in athletes with concentric abnormal geometry than in the other geometry groups, regardless of their field positions. Japanese young athletes may exhibit unique phenotypes of cardiac remodeling in association with their fitness characteristics. The four-tiered LV geometry classification potentially offers information regarding the subclinical cardiovascular risks of young athletes.
- 21 November 2022
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 45 (1) , 210-219
Development of a model predicting cardiac events in heart failure patients with decreased renal function: a retrospective study
Background Inappropriate and multiple medications affect the prognosis of patients with acute decompensated heart failure (ADHF). However, in ADHF patients with decreased renal function, there have been no reports on prognostic factors, including medication data, or models for predicting cardiac events. Aim To develop a model including medication data to predict cardiac events in ADHF patients with decreased renal function. Method This retrospective cohort study included 443 first-time admitted ADHF patients with decreased renal function (estimated glomerular filtration rate < 60 mL/min/1.73 m2 at discharge) in the Showa University Fujigaoka Hospital. The primary outcome was cardiac events within one year after discharge, defined as the composite of HF readmission, HF mortality, and cardiovascular mortality. The model for predicting cardiac events was developed using predictive factors extracted by multivariable analysis. The cardiac events curves were visualized using the Kaplan–Meier method and estimated using a log-rank test. Results The incidence of cardiac events within one year after discharge was 20.1%. By multivariable analysis, we observed that atrial fibrillation, weight loss < 5%, brain natriuretic peptide ≥ 200 pg/mL, polypharmacy, and beta-blockers use below target dosage were significantly associated with an increased risk of cardiac events. The developed model, the cardiac events rate in the high-risk group was significantly higher than in the low-risk group (41.0 vs. 9.2%, p < 0.001). Conclusion The developed model for predicting cardiac events will be useful in decision-making to support appropriate early management of ADHF patients with decreased renal function.
- 21 November 2022
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 45 (1) , 210-219
Development of a model predicting cardiac events in heart failure patients with decreased renal function: a retrospective study
Background Inappropriate and multiple medications affect the prognosis of patients with acute decompensated heart failure (ADHF). However, in ADHF patients with decreased renal function, there have been no reports on prognostic factors, including medication data, or models for predicting cardiac events. Aim To develop a model including medication data to predict cardiac events in ADHF patients with decreased renal function. Method This retrospective cohort study included 443 first-time admitted ADHF patients with decreased renal function (estimated glomerular filtration rate < 60 mL/min/1.73 m2 at discharge) in the Showa University Fujigaoka Hospital. The primary outcome was cardiac events within one year after discharge, defined as the composite of HF readmission, HF mortality, and cardiovascular mortality. The model for predicting cardiac events was developed using predictive factors extracted by multivariable analysis. The cardiac events curves were visualized using the Kaplan–Meier method and estimated using a log-rank test. Results The incidence of cardiac events within one year after discharge was 20.1%. By multivariable analysis, we observed that atrial fibrillation, weight loss < 5%, brain natriuretic peptide ≥ 200 pg/mL, polypharmacy, and beta-blockers use below target dosage were significantly associated with an increased risk of cardiac events. The developed model, the cardiac events rate in the high-risk group was significantly higher than in the low-risk group (41.0 vs. 9.2%, p < 0.001). Conclusion The developed model for predicting cardiac events will be useful in decision-making to support appropriate early management of ADHF patients with decreased renal function.
- Open Access
- 1 August 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 15 (8) , e012004
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
Background: The benefit of clopidogrel monotherapy after 1-month dual antiplatelet therapy (DAPT) compared with 12-month DAPT with aspirin and clopidogrel was demonstrated in the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2), but not in the STOPDAPT-2 acute coronary syndrome (ACS); however, both trials were underpowered based on the actual event rates. Methods: We obtained the prespecified pooled population of 5997 patients as the STOPDAPT-2 total cohort (STOPDAPT-2: N=3009/STOPDAPT-2 ACS: N=2988; ACS: N=4136/chronic coronary syndrome [CCS]: N=1861), comprising 2993 patients assigned to 1-month DAPT followed by clopidogrel monotherapy, and 3004 patients assigned to 12-month DAPT with aspirin and clopidogrel after percutaneous coronary intervention. The primary end point was the composite of cardiovascular (cardiovascular death, myocardial infarction, definite stent thrombosis, or any stroke) or bleeding (Thrombolysis in Myocardial Infarction major/minor) end points at 1 year. Results: One-month DAPT was noninferior to 12-month DAPT for the primary end point (2.84% versus 3.04%; hazard ratio [HR], 0.94 [95% CI, 0.70–1.27]; P noninferiority =0.001; P superiority =0.68). There was no significant risk-difference for the cardiovascular end point between the 1- and 12-month DAPT groups (2.40% versus 1.97%; HR, 1.24 [95% CI, 0.88–1.75]; P noninferiority =0.14; P superiority =0.23). There was a lower risk of the bleeding end point with 1-month DAPT relative to 12-month DAPT (0.50% versus 1.31%; HR, 0.38 [95% CI, 0.21–0.70]; P superiority =0.002). One-month DAPT relative to 12-month DAPT was associated with a lower risk for major bleeding regardless of ACS or CCS (ACS: HR, 0.46 [95% CI, 0.23–0.94]; P =0.03, and CCS: HR, 0.26 [95% CI, 0.09–0.79]; P =0.02; P interaction =0.40), while it was associated with a numerical increase in cardiovascular events in ACS patients, but not in CCS patients, although not statistically significant and without interaction (ACS: HR, 1.50 [95% CI, 0.99–2.27]; P =0.053, and CCS: HR, 0.74 [95% CI, 0.38–1.45]; P =0.39; P interaction =0.08). Conclusions: Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT with aspirin and clopidogrel had a benefit in reducing major bleeding events without being associated with increase in cardiovascular events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02619760, NCT03462498.
- 1 August 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 15 (8) , e012004
Open AccessClopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
Background: The benefit of clopidogrel monotherapy after 1-month dual antiplatelet therapy (DAPT) compared with 12-month DAPT with aspirin and clopidogrel was demonstrated in the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2), but not in the STOPDAPT-2 acute coronary syndrome (ACS); however, both trials were underpowered based on the actual event rates. Methods: We obtained the prespecified pooled population of 5997 patients as the STOPDAPT-2 total cohort (STOPDAPT-2: N=3009/STOPDAPT-2 ACS: N=2988; ACS: N=4136/chronic coronary syndrome [CCS]: N=1861), comprising 2993 patients assigned to 1-month DAPT followed by clopidogrel monotherapy, and 3004 patients assigned to 12-month DAPT with aspirin and clopidogrel after percutaneous coronary intervention. The primary end point was the composite of cardiovascular (cardiovascular death, myocardial infarction, definite stent thrombosis, or any stroke) or bleeding (Thrombolysis in Myocardial Infarction major/minor) end points at 1 year. Results: One-month DAPT was noninferior to 12-month DAPT for the primary end point (2.84% versus 3.04%; hazard ratio [HR], 0.94 [95% CI, 0.70–1.27]; P noninferiority =0.001; P superiority =0.68). There was no significant risk-difference for the cardiovascular end point between the 1- and 12-month DAPT groups (2.40% versus 1.97%; HR, 1.24 [95% CI, 0.88–1.75]; P noninferiority =0.14; P superiority =0.23). There was a lower risk of the bleeding end point with 1-month DAPT relative to 12-month DAPT (0.50% versus 1.31%; HR, 0.38 [95% CI, 0.21–0.70]; P superiority =0.002). One-month DAPT relative to 12-month DAPT was associated with a lower risk for major bleeding regardless of ACS or CCS (ACS: HR, 0.46 [95% CI, 0.23–0.94]; P =0.03, and CCS: HR, 0.26 [95% CI, 0.09–0.79]; P =0.02; P interaction =0.40), while it was associated with a numerical increase in cardiovascular events in ACS patients, but not in CCS patients, although not statistically significant and without interaction (ACS: HR, 1.50 [95% CI, 0.99–2.27]; P =0.053, and CCS: HR, 0.74 [95% CI, 0.38–1.45]; P =0.39; P interaction =0.08). Conclusions: Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT with aspirin and clopidogrel had a benefit in reducing major bleeding events without being associated with increase in cardiovascular events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02619760, NCT03462498.